Alpha Cognition Inc Dossier
Qualitative Analysis
Business overview
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, primarily Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI). The company's flagship product is ZUNVEYL (benzgalantamine), an FDA-approved oral delayed-release tablet indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. ZUNVEYL is chemically designed as a prodrug that bypasses the gastrointestinal tract in an inactive state, significantly reducing the severe gastrointestinal side effects commonly associated with traditional acetylcholinesterase inhibitors (AChEIs). Alpha Cognition is also developing a pipeline of preclinical and clinical assets, including a sublingual formulation of benzgalantamine, an intranasal formulation for mTBI, and gene therapy programs (ALPHA-0602, ALPHA-0702, and ALPHA-0802) delivering progranulin for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial footprint of ZUNVEYL (benzgalantamine) in the U.S. long-term care market. The initiative focuses on increasing nursing home penetration, expanding the prescriber base to approximately 2,000 active healthcare providers, and driving downstream pull-through from signed national PBM contracts.
Expected impact: Aims to accelerate sequential product sales growth, increase facility density, and support the company's target of reaching operating profitability in 2027.
Developing a sublingual formulation of ZUNVEYL designed for Alzheimer's patients suffering from dysphagia or severe swallowing difficulties. The company is advancing comparative pharmacokinetic (PK) studies versus tablet and intranasal formulations.
Expected impact: Provides a disruptive treatment option for the estimated 20% of moderate-to-severe Alzheimer's patients with swallowing difficulties, expanding the addressable market.
Conducting three distinct clinical and real-world studies (BEACON, CONVERGE, and RESOLVE) to generate robust data on ZUNVEYL's tolerability, behavioral outcomes, and impact on polypharmacy in complex patient populations.
Expected impact: Strengthens the clinical and economic value proposition of ZUNVEYL to overcome payer friction, support reimbursement, and drive physician adoption.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants CMS exclusive rights to develop, manufacture, and commercialize ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia, and New Zealand. CMS is responsible for all regulatory and commercialization activities in these territories.
Terms: Total agreement value of up to $44 million, including $6 million in upfront payments split into tranches, plus regulatory and commercial milestone payments and double-digit royalties on net sales.